Gutless adenovirus: Last-generation adenovirus for gene therapy

Gene Therapy

Volumn 12, Issue , 2005, Pages S18-S27

  Alba, R ^a   Bosch, A ^a   Chillon, M ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Adenovirus; Gutless; Helper dependent vectors; In vivo gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DYSTROPHIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; MIFEPRISTONE; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; T LYMPHOCYTE ANTIBODY; TACROLIMUS; TAMOXIFEN; TETRACYCLINE; VIRUS PROTEIN;

CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE TRANSFER; HELPER VIRUS; HUMAN; IN VIVO STUDY; LIVER; MUSCLE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RODENT; VIRAL CONTAMINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINATION;

ADENOVIRIDAE; ANIMALS; BIOTECHNOLOGY; CAPSID; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HELPER VIRUSES; HUMANS; IMMUNOTHERAPY; PROMOTER REGIONS (GENETICS);

ADENOVIRIDAE; PARVOVIRUS; PRIMATES; RODENTIA;

EID: 27544513676     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302612     Document Type: Article

References (118)

1. Horwitz MS. Adenoviridae and their replication. Virology 1990; 2: 1679-1720.
2. Danthinne X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Therapy 2000; 7: 1707-1714.
3. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
4. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
5. Schiedner G, Hertel S, Kochanek S. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 2000; 11: 2105-2116.
6. Fallaux FJ et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication- competent adenoviruses. Hum Gene Ther 1998; 9: 1909-1917.
7. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
8. Amalfitano A et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
9. Armentano D et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408-2416.
10. Alemany R et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods 1997; 68: 147-159.
11. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
12. Ghosh-Choudhury G, Graham FL. Stable transfer of a mouse dihydrofolate reductase gene into a deficient cell line using human adenovirus vector. Biochem Biophys Res Commun 1987; 147: 964-973.
13. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus- dependent adenovirus vector. Proc Natl Acad Sci USA 1995; 92: 3854-3858.
14. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71: 3293-3298.
15. Parks R, Evelegh C, Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Therapy 1999; 6: 1565-1573.
16. Schiedner G et al. Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol 2002; 76: 1600-1609.
17. Sandig V et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 2000; 97: 1002-1007.
18. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003; 8: 846-852.
19. Sato M, Suzuki S, Kubo S, Mitani K. Replication and packaging of helper-dependent adenoviral vectors. Gene Therapy 2002; 9: 472-476.
20. Soudais C, Skander N, Kremer EJ. Long-term in vivo transduction of neurons throughout the rat CNS using novel helper- dependent CAV-2 vectors. FASEB J 2004; 18: 391-393.
21. Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
22. Silver DP, Livingston DM. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol Cell 2001; 8: 233-243.
23. Zang Y, Schneider R. Adenovirus inhibition of cellular protein synthesis and the specific translation of late viral mRNA. Semin Virol 1993; 4: 233-243.
24. Ng PG, Graham FL. Helper-dependent adenoviral vectors for gene therapy. In: Templeton NS (ed). Gene and Cell Therapy. Marcel Dekker Inc: New York, 2004 pp 53-70.
25. Som T, Armstrong KA, Volkert FC, Broach JR. Autoregulation of 2 micron circle gene expression provides a model for maintenance of stable plasmid copy levels. Cell 1988; 52: 27-37.
26. Ng P et al. Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 2001; 3: 809-815.
27. Groth AC, Olivares EC, Thyagarajan B, Calos MP. A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci USA 2000; 97: 5995-6000.
28. Sargent KL et al. Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors. Gene Therapy 2004; 11: 504-511.
29. Kubo S, Saeki Y, Chiocca EA, Mitani K. An HSV amplicon- based helper system for helper-dependent adenoviral vectors. Biochem Biophys Res Commun 2003; 307: 826-830.
30. Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Therapy 2001; 8: 846-854.
31. Graham FL. Growth of 293 cells in suspension culture. J Gen Virol 1987; 68 (Pt 3): 937-940.
32. Sakhuja K et al. Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 2003; 14: 243-254.
33. Schagen FH, Ossevoort M, Toes RE, Hoeben RC. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 2004; 50: 51-70.
34. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
35. Liu Q et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003; 14: 627-643.
36. Schnell MA et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722.
37. Molinier-Frenkel V et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74: 7678-7682.
38. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241-251.
39. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increases the safety, efficacy and persistence of adenovirusmediated gene transfer in vivo. Gene Therapy 1997; 4: 309-316.
40. Wolff G et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-629.
41. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
42. Fang B et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
43. Kaplan JM, Smith AE. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 1997; 8: 1095-1104.
44. Kuriyama S et al. Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver. Int J Cancer 2000; 85: 839-844.
45. Otake K, Ennist DL, Harrod K, Trapnell BC. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 1998; 9: 2207-2222.
46. Zuckerman JB et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10: 2973-2985.
47. Poller W et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Therapy 1996; 3: 521-530.
48. Sawchuk SJ et al. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum Gene Ther 1996; 7: 499-506.
49. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
50. Kay MA et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686-4691.
51. Stein CS, Pemberton JL, van Rooijen N, Davidson BL. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Therapy 1998; 5: 431-439.
52. Wilson CB et al. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J Virol 1998; 72: 7542-7550.
53. DeMatteo RP et al. Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. J Virol 1997; 71: 5330-5335.
54. Ilan Y et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998; 27: 1368-1376.
55. Mastrangeli A et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
56. Morral N et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
57. Fitzgerald JC et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003; 170: 1416-1422.
58. Kremer EJ, Boutin S, Chillon M, Danos O. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 2000; 74: 505-512.
59. Chillon M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Therapy 1998; 5: 995-1002.
60. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792-4801.
61. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13: 1887-1900.
62. Lochmuller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. Biochem Biophys Res Commun 1995; 213: 569-574.
63. Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirusmediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
64. Chen HH et al. DNA from both high-capacity and firstgeneration adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999; 10: 365-373.
65. Maione D et al. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 2000; 11: 859-868.
66. Morsy MA et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
67. O'Neal WK et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 2000; 6: 179-195.
68. Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat Genet 1998; 18: 180-183.
69. Roth MD et al. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol 2002; 169: 4651-4656.
70. Muruve DA et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 2004; 78: 5966-5972.
71. De Geest BR, Van Linthout SA, Collen D. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood 2003; 101: 2551-2556.
72. Brown BD et al. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost 2004; 2: 111-118.
73. Kremer EJ. CAR chasing: canine adenovirus vectors-all bite and no bark? J Gene Med 2004; 6 (Suppl 1): S139-S151.
74. Thomas CE et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000; 97: 7482-7487.
75. Thomas CE et al. Pre-existing antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther 2001; 12: 839-846.
76. Brunetti-Pierri N et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
77. Croyle MA et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Therapy 2005; 12: 579-587.
78. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005; 11: 66-79.
79. Harui A et al. Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Gene Therapy 2004; 11: 1617-1626.
80. Chen HH et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997; 94: 1645-1650.
81. Kim IA et al. Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas. Int J Oncol 2001; 19: 1041-1047.
82. Morral N et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709-2716.
83. Ehrhardt A et al. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 2003; 102: 2403-2411.
84. Reddy PS et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 2002; 5: 63-73.
85. Belalcazar LM et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-2732.
86. Oka K et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103: 1274-1281.
87. Pastore L et al. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 2004; 327: 153-160.
88. Mian A et al. Long-term correction of ornithine transcarbamy- lase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol Ther 2004; 10: 492-499.
89. Kojima H et al. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 2003; 9: 596-603.
90. Aurisicchio L et al. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J Virol 2000; 74: 4816-4823.
91. Fiedler M et al. Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN- alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J Virol 2004; 78: 10111-10121.
92. Pastore L et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-1781.
93. Kass-Eisler A et al. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Therapy 1996; 3: 154-162.
94. Mack CA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
95. Roy S, Shirley PS, McClelland A, Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 1998; 72: 6875-6879.
96. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 1998; 9: 1419-1427.
97. Burcin MM et al. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 1999; 96: 355-360.
98. Salucci V et al. Tight control of gene expression by a helper- dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Therapy 2002; 9: 1415-1421.
99. Zerby D et al. In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system. Hum Gene Ther 2003; 14: 749-761.
100. Ehrhardt A, Xu H, Kay MA. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol 2003; 77: 7689-7695.
101. Bramson JL et al. Helper-dependent adenoviral vectors containing modified fiber for improved transduction of developing and mature muscle cells. Hum Gene Ther 2004; 15: 179-188.
102. Biermann V et al. Targeting of high-capacity adenoviral vectors. Hum Gene Ther 2001; 12: 1757-1769.
103. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome- linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984; 81: 1189-1192.
104. Dudley RW et al. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther 2004; 15: 145-156.
105. Gilbert R et al. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 2003; 12: 1287-1299.
106. Bilbao R et al. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. Gene Therapy 2005; 12: 39-47.
107. DelloRusso C et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 2002; 99: 12979-12984.
108. Zou L, Zhou H, Pastore L, Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2000; 2:105-113.
109. Thomas CE et al. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 2001; 3: 36-46.
110. Semkova I et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci USA 2002; 99: 13090-13095.
111. Oshima Y et al. Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization. J Cell Physiol 2004; 199: 399-411.
112. Fleury S et al. Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors. Basic Res Cardiol 2004; 99: 247-256.
113. Tuettenberg A et al. Early adenoviral gene expression mediates immunosuppression by transduced dendritic cell (DC): implications for immunotherapy using genetically modified DC. J Immunol 2004; 172: 1524-1530.
114. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004; 110: 1484-1491.
115. Koehler DR et al. Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci USA 2003; 100: 15364-15369.
116. Goncalves MA et al. Transfer of the full-length dystrophin- coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol 2005; 79: 3146-3162.
117. Yant SR et al. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 2002; 20: 999-1005.
118. Kreppel F, Kochanek S. Long-term transgene expression in proliferating cells mediated by episomally maintained highcapacity adenovirus vectors. J Virol 2004; 78: 9-22.